<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170104</url>
  </required_header>
  <id_info>
    <org_study_id>CAUHHO 2009-1</org_study_id>
    <nct_id>NCT01170104</nct_id>
  </id_info>
  <brief_title>Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chung-Ang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the time to progression of the combination therapy of Transcatheter Arterial
      Chemoembolization (TACE) and sorafenib in patients with previously untreated advanced or
      metastatic hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 year</time_frame>
    <description>Assessments including image and laboratory studies will take place within 7days of the every TACE cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicity profiles</measure>
    <time_frame>2 year</time_frame>
    <description>Clinically assessed every TACE cycle</description>
  </secondary_outcome>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE (Transcatheter arterial chemoembolization)</intervention_name>
    <description>Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unresectable Hepatocellular carcinoma with local liver lesion treatable with TACE

          2. Age &gt; 18 years.

          3. ECOG Performance Status of 0 or 1.

          4. Child-Pugh class A (class B could be included when Childs score is 7).

          5. Life expectancy of at least 12 weeks.

          6. Subjects with at least one measurable lesion.

          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  Hemoglobin &gt; 9.0 g/dl

               -  Absolute neutrophil count (ANC) &gt;1,500/mm3

               -  Platelet count &gt; 75,000/Î¼l

               -  Total bilirubin &lt; 1.5 times the upper limit of normal

               -  ALT and AST &lt; 2.5 x upper limit of normal (UNL)

               -  Alkaline phosphatase &lt; 5 x ULN

               -  PT-INR/PTT &lt; 1.5 x upper limit of normal

               -  Serum creatinine &lt; 1.5 x ULN

          8. Signed and dated informed consent before the start of specific protocol procedures

        Exclusion Criteria:

          1. History of cardiac disease: congestive heart failure &gt;NYHA class 2; active CAD (MI
             more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring
             anti-arrythmic therapy( beta blockers or digoxin are permitted) or uncontrolled
             hypertension.

          2. History of HIV infection.

          3. Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)

          4. Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months
             from definitive therapy, has a negative imaging study within 4 weeks of study entry
             and is clinically stable with respect to the tumor at the time of study entry)

          5. Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics)

          6. History of organ allograft The organ allograft may be allowed as protocol specific.

          7. Patients with evidence or history of uncontrolled bleeding diathesis

          8. Patients undergoing renal dialysis

          9. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively
             treated &gt; 3 years prior to study entry.

         10. Excluded therapies and medications, previous and concomitant:

               -  Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of
                  study entry

               -  Radiotherapy during study or within 3 weeks of start of study drug. (Palliative
                  radiotherapy will be allowed). Major surgery within 4 weeks of start of study

               -  Investigational drug therapy outside of this trial during or within 4 weeks of
                  study entry

               -  Prior exposure to the study drug.

               -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
                  negative pregnancy test performed within 7 days of the start of treatment. Both
                  men and women enrolled in this trial must use adequate barrier birth control
                  measures during the course of the trial (and men for at least 3 months after last
                  administration of study medication).

               -  Substance abuse, medical, psychological or social conditions that may interfere
                  with the patient's participation in the study or evaluation of the study results

               -  Any condition that is unstable or could jeopardize the safety of the patient and
                  their compliance in the study

               -  Patients unable to swallow oral medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joung-Soon Jang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joung-Soon Jang, M.D.</last_name>
    <phone>82-2-6299-1427</phone>
    <email>alsaba@daum.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>In Gyu Hwang, M.D.</last_name>
    <phone>82-2-748-9786</phone>
    <email>higyu72@yahoo.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Dongjak</city>
        <state>Seoul</state>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joung-Soon Jang, M.D.</last_name>
      <phone>82-2-6299-1427</phone>
      <email>alsaba@daum.net</email>
    </contact>
    <contact_backup>
      <last_name>In Gyu Hwang, M.D.</last_name>
      <phone>82-2-748-9786</phone>
      <email>higyu72@yahoo.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Joung-Soon Jang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyung Joon Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Woong Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>In Gyu Hwang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joung-Soon Jang/Professor</name_title>
    <organization>Chung-Ang University Hospital</organization>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>TACE</keyword>
  <keyword>locally, advanced Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

